Access
Email Verification
Agenda 2024
DAY 1: MONDAY, 24 JUNE, 2024
0830 - 0930 REGISTRATION AND MORNING REFRESHMENTS
0930 - 0940 OPENING ADDRESS
0940 - 1005 STICKING POINT: THE IMPACT OF INNOVATION ON DRUG DELIVERY DEVICES
- Introducing patient-focused device design: more digital and convenient
- Looking at the designing success: strategic imperatives for the industry
- Getting real with environmental sustainability
Aaron Wright
IQVIA
IQVIA
1005 - 1010 Q&A SESSION ON EXPLORING INNOVATION IN DRUG DELIVERY AND SUSTAINABILITY
1010 - 1030 SPEED NETWORKING SESSION
- Exchange business cards and get connected in short one-to-one meetings
- Start the conversation to arrange a more formal meeting later on in the conference
- Share your professional background and discuss your biggest business issues - Don't forget your business cards!
Conference Host
1030 - 1100 MORNING COFFEE BREAK IN THE EXHIBIT AREASPONSORED BY MUNIT SA
1100 - 1125 MATERIAL SCIENCE – GET IT RIGHT!
- Amorphous content in materials using innovative approaches
- Physical forms in material science for enhanced understanding
- Utilising Raman imaging for precise particle statistics in materials
Mridul Majumder
M2M Pharmaceuticals
M2M Pharmaceuticals
1125 - 1130 Q&A SESSION ON UNDERSTANDING THE MATERIAL SCIENCE THROUGH INNOVATIVE TECHNIQUES
1130 - 1155 EVOLUTION OF A (P)REFILLABLE DPI
- Initial development of a high payload blister-based reusable/refillable single-dose device
- High-performance delivery engine and optimisation using computational fluid dynamics
- Potential to use the device in future products, e.g. biologics and acute use applications
Phil Swanbury
Vectura
Vectura
1155 - 1200 Q&A SESSION ON ADVANCEMENTS IN (P)REFILLABLE DPI TECHNOLOGY
1200 - 1330 NETWORKING LUNCH & VISITING THE DRUG DELIVERY EXHIBITION
1330 - 1355 BIO-COURIER TECHNOLOGY: NEW MANUFACTURING METHOD FOR NA DELIVERY
- NA introduction during particle formation limits LNP effectiveness
- Significant NA loss in manufacturing leads to efficiency challenges
- Traditional LNPs require ultra-cold storage and shipping conditions
- Bio-Courier technology separates particle formation from NA loading
Suzanne Saffie-Siebert
SiSaf
SiSaf
1355 - 1400 Q&A SESSION ON IMPROVED NUCLEIC ACID DELIVERY BY BIO-COURIER
1400 - 1425 INTRODUCING THE VISCOSITY REDUCTION PLATFORM FOR PROTEIN FORMULATIONS
- Viscosity reduction platform enabling subcutaneous delivery of concentrated proteins
- Leveraging machine learning for excipient selection in viscosity reduction applications
Tobias Rosenkranz
Merck
Merck
1425 - 1430 Q&A SESSION ON THE IMPACT OF EXCIPIENT ON VISCOSITY REDUCTION
1430 - 1500 AFTERNOON COFFEE BREAK IN THE EXHIBIT AREASPONSORED BY MYBIOTECH GMBH
1500 - 1525 ANTIDEPRESSANT-INDUCED MEMBRANE TRAFFICKING AND BLOOD-BRAIN BARRIER
- Exploring SSRIs' role in fluid-phase uptake and membrane trafficking
- Analysing enhanced endocytosis and its impact on the blood-brain barrier function
- Evaluating antidepressants for potential repurposing in brain drug delivery
Oleg Glebov
King's College London
King's College London
1525 - 1530 Q&A SESSION ON BLOOD-BRAIN BARRIER MODULATION USING ANTIDEPRESSANT
1530 - 1555 2D PRINTING TECHNOLOGY FOR ORAL DRUG DELIVERY TO PREMATURE INFANTS
- The intersection of neonatal care and precision medicine through 2D printing technology
- Manufacturing process of a stable hydrocortisone ink formulated to the final orodispersible film
- Showcasing the results and future directions in the development of hydrocortisone ODF
Bernd Sterner
Gen-Plus
Gen-Plus
1555 - 1600 Q&A SESSION ON EXPLORING INNOVATIVE 2D PRINTING TECHNOLOGY IN NEONATAL DRUG DELIVERY
1600 - 1625 PHARMACEUTICAL APPLICATIONS OF NUTRACEUTICALS AND CANNABINOIDS
- Emerging formulation technologies for addressing severe malabsorption
- Safety and efficacy considerations associated with compliance and long-term
- Formulation for product dosage forms and site of application
Andreas Papas
Antares Health Products
Antares Health Products
1625 - 1630 Q&A SESSION ON NUTRACEUTICAL AND CANNABINOID APPLICATIONS IN PHARMA
1630 - 1730 NETWORKING DRINKS RECEPTION
DAY 2: TUESDAY, 25 JUNE, 2024
0900 - 0930 MORNING REFRESHMENTS
0930 - 0940 OPENING ADDRESS
0940 - 1005 THE IMPACT OF HUMAN FACTORS ON NEW DRUG DELIVERY TECHNOLOGIES
- The critical role of human considerations in the design of injection devices
- Addressing the current challenges faced by home-use drug delivery systems
- The regulatory landscape for device approval with a focus on human factors
David Grosse-Wentrup
Design Science
Design Science
1005 - 1010 Q&A SESSION ON HUMAN FACTORS IN DRUG DELIVERY TECHNOLOGY DEVELOPMENT
1010 - 1035 EXPLORING A NEEDLE-FREE TRANSDERMAL LARGE MOLECULE DELIVERY
- Introducing a non-invasive way to deliver drugs like insulin without needles
- Breakthrough in the first wearable device using ultrasound for drug delivery
- Revolutionising drug delivery with a sustainable, smart, and safe platform
Eduardo Jorgensen
Medicsen
Medicsen
1035 - 1040 Q&A SESSION ON REVOLUTIONISING DRUG DELIVERY WITH SONOPHORESIS PATCH
1040 - 1105 NOVEL DRUG DELIVERY SYSTEM WITH IMMUNE CELLS AND NANOPARTICLES
- Unique drug delivery method combining immune cells and nanoparticles
- The “on-demand” release mechanism of the drug in response to stimuli
- Targeted release evidences in in-vitro and in-vivo for various disease models
Sami Ullah
Sartorius
Sartorius
1105 - 1110 Q&A SESSION ON THE INNOVATIONS IN TARGETED DRUG DELIVERY SYSTEMS
1110 - 1130 MORNING COFFEE BREAK IN THE EXHIBIT AREASPONSORED BY PHARMALEX GMBH
1130 - 1155 NANO-API FORMULATION FOR ENHANCED DRUG DELIVERY AND IMPROVED PATIENT COMPLIANCE
- Enhancing the solubility of water-insoluble APIs using advanced nano-sizing techniques
- Stabilizing nano-sized APIs with a carrier system and applying gastro-resistant coatings
- Controlled API release and the benefits of stick pack packaging for patient compliance
Michael Black
BENEO
BENEO
1155 - 1200 Q&A SESSION ON DRUG DELIVERY THROUGH NANO-API FORMULATION
1200 - 1225 COMPLEX CMC TRADE-OFFS IN PERSONALISED CANCER VACCINES
- Exploring control strategies and specification panels in cancer vaccine development
- Examining the stability challenges of individual therapeutic cancer vaccines
Ilona Baraniak-Lang
PharmaLex
PharmaLex
1225 - 1230 Q&A SESSION ON CANCER VACCINE DEVELOPMENT AND RELATED CMC TRADE-OFFS
1230 - 1255 AAV-MEDIATED DELIVERY OF THE CAS9 NICKASE FOR GENE EDITING THERAPY
- CAG/CTG repeats linked to 15 neurological disorders are yet without treatment
- Targeted Cas9 nickase corrects mutations in vitro across multiple cell types
- In mouse brains, Cas9 nickase induces over 50% editing efficiency
Antoine Mangin
Cardiff University
Cardiff University
1255 - 1300 Q&A SESSION ON CAS9 NICKASE GENE EDITING THERAPY THROUGH AVV-MEDIATED DELIVERY
1300 - 1315 FEEDBACK & RAFFLE DRAW
1315 - 1430 NETWORKING LUNCH
Quick Proposal
Key topics for 2024:
- Formulation design for poorly soluble compounds
Understand the most recent technological advancements to improve the dissolution and bioavailability of poorly soluble drugs. - New drug delivery technologies for better deliverability
The future of drug deliveries across the skin barrier to the systemic circulation via Iontophoresis, electroporation, sonophoresis, magnetophoresis, dermal patches, nanocarriers, and needled and needle-less shots. - Latest developments in controlled released technologies
Evaluate controlled release methods that enhance drug therapy's safety, efficacy, reliability, and convenience by controlling the rate and duration of drug release to control drug actions. - Optimising drug formulations for continuous manufacturing
Learn about new methods in continuous manufacturing for the pharmaceutical industry, which offers the potential for cost reduction, enhanced efficiency, and economic viability. - Overcoming the blood-brain barrier and re-engineering biologics
Looking at the structural elements and anatomical features of the blood-brain barrier, various in vivo, in situ blood-brain barrier models, and adopting molecular Trojan horse technologies. - Developing new drug modalities and biotherapeutics
Achieve a deeper understanding of biotherapeutics and novel drug modalities beyond traditional small molecules, including RNA-based approaches, targeted protein degradation, covalent inhibitors, next-generation peptides, and antibodies.
Sponsorship Opportunities
Join us as a sponsor for this IQ International conference! Reach your target audience, limit competitor influence at the conference and become a keynote speaker, while sharing your company's solutions for this industry.
- Get registration discounts
- Enhance your brand awareness
- Additional marketing opportunities